166 related articles for article (PubMed ID: 31456347)
1. The Application of Biomaterials in the Treatment of Platinum-Resistant Ovarian Cancer.
Levy A; Leynes C; Baig M; Chew SA
ChemMedChem; 2019 Nov; 14(21):1810-1827. PubMed ID: 31456347
[TBL] [Abstract][Full Text] [Related]
2. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
Saldivar JS; Wu X; Follen M; Gershenson D
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review.
Binju M; Padilla MA; Singomat T; Kaur P; Suryo Rahmanto Y; Cohen PA; Yu Y
Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):371-378. PubMed ID: 30423357
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36.
Jayawardhana AMDS; Stilgenbauer M; Datta P; Qiu Z; Mckenzie S; Wang H; Bowers D; Kurokawa M; Zheng YR
Chem Commun (Camb); 2020 Sep; 56(73):10706-10709. PubMed ID: 32789350
[TBL] [Abstract][Full Text] [Related]
5. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance.
Xie P; Wang Y; Wei D; Zhang L; Zhang B; Xiao H; Song H; Mao X
J Mater Chem B; 2021 Jul; 9(26):5173-5194. PubMed ID: 34116565
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
McKeage MJ; Abel G; Kelland LR; Harrap KR
Br J Cancer; 1994 Jan; 69(1):1-7. PubMed ID: 8286188
[TBL] [Abstract][Full Text] [Related]
8. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
[TBL] [Abstract][Full Text] [Related]
9. Dual-action organoplatinum polymeric nanoparticles overcoming drug resistance in ovarian cancer.
Jayawardhana AMDS; Qiu Z; Kempf S; Wang H; Miterko M; Bowers DJ; Zheng YR
Dalton Trans; 2019 Sep; 48(33):12451-12458. PubMed ID: 31353381
[TBL] [Abstract][Full Text] [Related]
10. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
[TBL] [Abstract][Full Text] [Related]
11. Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives-An In Vitro Study.
Michalak M; Lach MS; Antoszczak M; Huczyński A; Suchorska WM
Molecules; 2020 Jan; 25(3):. PubMed ID: 31991882
[TBL] [Abstract][Full Text] [Related]
12. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer.
Piccart MJ; Lamb H; Vermorken JB
Ann Oncol; 2001 Sep; 12(9):1195-203. PubMed ID: 11697824
[TBL] [Abstract][Full Text] [Related]
13. Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate.
Arambula JF; Sessler JL; Siddik ZH
Bioorg Med Chem Lett; 2011 Mar; 21(6):1701-5. PubMed ID: 21345675
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer.
Schumann C; Chan S; Khalimonchuk O; Khal S; Moskal V; Shah V; Alani AW; Taratula O; Taratula O
Mol Pharm; 2016 Jun; 13(6):2070-83. PubMed ID: 27170529
[TBL] [Abstract][Full Text] [Related]
16. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
17. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
Mellish KJ; Barnard CF; Murrer BA; Kelland LR
Int J Cancer; 1995 Sep; 62(6):717-23. PubMed ID: 7558420
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
[TBL] [Abstract][Full Text] [Related]
19. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
20. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
